Rectal Cancer Clinical Trial
Official title:
Randomized Phase II Study of SOX vs mFOLFOX6 as Neoadjuvant Chemotherapy in Patients With Resectable Rectal Cancer (KSCC1301).
To evaluate the efficacy and safety of SOX or mFOLFOX6 as neoadjuvant chemotherapy in patients with resectable rectal cancer, and to identify the more promising regimen.
Status | Recruiting |
Enrollment | 110 |
Est. completion date | August 2020 |
Est. primary completion date | August 2018 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 20 Years and older |
Eligibility |
Inclusion Criteria: - Written informed consent - Patients who are judged to be suitable for receiving this protocol therapy by physician - Distal border of tumor is located under the peritoneal reflection - Histologically confirmed rectal adenocarcinoma - Previously untreated rectal cancer - Within 28 days before registration, the tumor is considered by the surgeon to be amenable to curative resection [T category: cSS and cSE, cSI, cA, cAI. N category: cN0-2 and cN3(#253 lymph node)] - Within 28 days before registration, there is no evidence of distant metastasis by contrast-enhanced CT - >= 20 years old - PS (ECOG) 0-1 - Be able to take oral drugs - Required baseline laboratory parameters (within 14 days before registration): WBC >= 3000 ,<12000/mm3, Neu >= 1,500/ mm3, Hb >= 9.0g/dl, Plt >= 100,000/ mm3, T-Bil <= 2.0mg/dl, AST,ALT <= 100U/L, Cre <1.5mg/dl, Ccr >= 60mL/min - Considered to survive for more than 3 months Exclusion Criteria: - History of serious drug hypersensitivity or a history of drug allergy - Pregnant or lactating woman and man who hope for Partner's pregnant - Active infection(over 38 degree) - Serious complication ( ex. interstitial pneumonitis, pulmonary fibrosis, renal failure, liver failure, serious diabetes, serious hypertension) - Clinically significant abnormal electrocardiogram or heart disease - Serious diarrhea - Pleural effusion, peritoneal fluid that needs treatment - Previous history of serious lung disorder ( ex. interstitial lung disease or fibrosis, serious emphysema ) - Hemorrhagic diathesis, coagulation disorder - Active double cancer (synchronous double cancer or asynchronous double cancer with disease-free duration of 5 years or less) - Patients who need flucytosine, phenytoin or warfarin potassium - Requiring steroid drug - Patients with contraindication to therapy - History of allergy to contrast material - Serious stricture (exclude the patients who are put in stoma) - Positive for HBs antigen and HCV antibody - Not appropriate for the study at the physician's assessment |
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
Japan | Kyushu University Hospital | Fukuoka | |
Japan | Kurume University Hospital | Kurume |
Lead Sponsor | Collaborator |
---|---|
Clinical Research Support Center Kyush |
Japan,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | 3-years Disease Free Survival rate | The last analysis after the follow-up period is conducted. The disease-free survival ratio that assumed full analysis set (FAS) as a denominator is estimating by Kaplan-Meier method at 3 year, up to 5 years after the last subject enrollment. | 3 years from the enrollment | Yes |
Secondary | Pathological Effect | The pathological effect of protocol treatment as FAS a denominator is evaluated according to the criteria of Japanese Classification of Colorectal Carcinoma 7th revision | After operation, up to 5 years after the last subject enrollment. | No |
Secondary | R0 resection rate | The R0 resection rate is defined as a ratio of case that conducted R0 resection in FAS. | At operation, up to 5 years after the last subject enrollment. | No |
Secondary | Completion rate of each modality (neoadjuvant chemotherapy, operation and adjuvant chemotherapy) | The rate completed 4 courses of neo-adjuvant chemotherapy within protocol treatment is defined as the completion rate of neo-adjuvant therapy in FAS. Among the cases that an resection operation are enforced and that adjuvant chemotherapy is planned after the operation, the rate completed 4 courses of adjuvant chemotherapy within protocol treatment is defined as the completion rate of adjuvant therapy | After completion of protocol treatment, up to 5 years after the last subject enrollment. | Yes |
Secondary | Overall survival (OS) | Overall survival is defined as a period from an enrollment date to a death from every cause in FAS. | Up to 5 years after the last subject enrollment. | Yes |
Secondary | Disease Free survival (DFS) | DFS is defined as the period from a registration day to the day of recurrence, the day of diagnosis of secondary cancer and the day of the death of every cause in FAS. | The date of recurrence, occurrence of secondary cancer and death, up to 5 years after the last subject enrollment. | Yes |
Secondary | OS in patients with R0 resection | OS in patients with R0 resection is defined as a period from a enrollment day to the date of death from every cause in patients with R0 resection in FAS. | At the date of death, up to 5 years after the last subject enrollment. | Yes |
Secondary | DFS in patients with R0 resection | DFS in patients with R0 resection is defined as the period from a enrollment day to the day of recurrence, the day of diagnosis of secondary cancer and the day of the death of every cause in patients with R0 resection in FAS. | The date of recurrence, occurrence of secondary cancer and death, up to 5 years after the last subject enrollment. | Yes |
Secondary | Transition rate to Operation | The transition rate to operation is defined as the rate of case transited to the resection operation in FAS. | At the operation, up to 5 years after the last subject enrollment. | No |
Secondary | local recurrence rate (per operated population) | The local recurrence rate is defined as the recurrence rate of operated population. | After the operation, up to 5 years after the last subject enrollment. | No |
Secondary | Safety | The frequency of worst Grade of the adverse event (toxicity) in all courses with the CTCAE v4.0 Japanese translated JCOG version is calculated in each group about the cases for the safety analysis a denominator | Within protocol treatment, up to 5 years after the last subject enrollment. | Yes |
Secondary | Pattern of first recurrence | Pattern of first recurrence is investigated in FAS. | At the study completion, up to 5 years after the last subject enrollment. | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT06380101 -
Evaluating a Nonessential Amino Acid Restriction (NEAAR) Medical Food With Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer (LARC)
|
N/A | |
Active, not recruiting |
NCT05551052 -
CRC Detection Reliable Assessment With Blood
|
||
Recruiting |
NCT04323722 -
Impact of Bladder Depletion on Mesorectal Movements During Radiotherapy in Rectal Cancer
|
N/A | |
Recruiting |
NCT06006390 -
CEA Targeting Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of CEA Positive Advanced Solid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT04088955 -
A Digimed Oncology PharmacoTherapy Registry
|
||
Active, not recruiting |
NCT01347697 -
Collagen Implant (Biological Mesh) Versus GM Flap for Reconstruction of Pelvic Floor After ELAPE in Rectal Cancer
|
N/A | |
Recruiting |
NCT04495088 -
Preoperative FOLFOX Versus Postoperative Risk-adapted Chemotherapy in Patients With Locally Advanced Rectal Cancer
|
Phase 3 | |
Withdrawn |
NCT03007771 -
Magnetic Resonance-guided High-Intensity Focused Ultrasound (MR-HIFU) Used for Mild Hyperthermia
|
Phase 1 | |
Terminated |
NCT01347645 -
Irinotecan Plus E7820 Versus FOLFIRI in Second-Line Therapy in Patients With Locally Advanced or Metastatic Colon or Rectal Cancer
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT03520088 -
PROSPECTIVE CONTROLLED AND RANDOMIZED STUDY OF THE GENITOURINARY FUNCTION AFTER RECTAL CANCER SURGERY IN RELATION TO THE DISSECTION OF THE INFERIOR MESENTERIC VESSELS
|
N/A | |
Recruiting |
NCT05556473 -
F-Tryptophan PET/CT in Human Cancers
|
Phase 1 | |
Recruiting |
NCT04749381 -
The Role of TCM on ERAS of Rectal Cancer Patients
|
Phase 2 | |
Enrolling by invitation |
NCT05028192 -
Mitochondria Preservation by Exercise Training: a Targeted Therapy for Cancer and Chemotherapy-induced Cachexia
|
||
Recruiting |
NCT03283540 -
Transanal Total Mesorectal Excision for Rectal Cancer on Anal Physiology + Fecal Incontinence
|
||
Completed |
NCT04534309 -
Behavioral Weight Loss Program for Cancer Survivors in Maryland
|
N/A | |
Recruiting |
NCT05914766 -
An Informational and Supportive Care Intervention for Patients With Locally Advanced Rectal Cancer
|
N/A | |
Recruiting |
NCT04852653 -
A Prospective Feasibility Study Evaluating Extracellular Vesicles Obtained by Liquid Biopsy for Neoadjuvant Treatment Response Assessment in Rectal Cancer
|
||
Recruiting |
NCT03190941 -
Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients
|
Phase 1/Phase 2 | |
Terminated |
NCT02933944 -
Exploratory Study of TG02-treatment as Monotherapy or in Combination With Pembrolizumab to Assess Safety and Immune Activation in Patients With Locally Advanced Primary and Recurrent Oncogenic RAS Exon 2 Mutant Colorectal Cancer
|
Phase 1 | |
Completed |
NCT02810652 -
Perioperative Geriatrics Intervention for Older Cancer Patients Undergoing Surgical Resection
|
N/A |